Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Stromal architecture directs early dissemination in pancreatic ductal adenocarcinoma
Arja Ray, Mackenzie K. Callaway, Nelson J. Rodríguez-Merced, Alexandra L. Crampton, Marjorie Carlson, Kenneth B. Emme, Ethan A. Ensminger, Alexander A. Kinne, Jonathan H. Schrope, Haley R. Rasmussen, Hong Jiang, David G. DeNardo, David K. Wood, Paolo P. Provenzano
Arja Ray, Mackenzie K. Callaway, Nelson J. Rodríguez-Merced, Alexandra L. Crampton, Marjorie Carlson, Kenneth B. Emme, Ethan A. Ensminger, Alexander A. Kinne, Jonathan H. Schrope, Haley R. Rasmussen, Hong Jiang, David G. DeNardo, David K. Wood, Paolo P. Provenzano
View: Text | PDF
Research Article Cell biology Oncology

Stromal architecture directs early dissemination in pancreatic ductal adenocarcinoma

  • Text
  • PDF
Abstract

Pancreatic ductal adenocarcinoma (PDA) is an extremely metastatic and lethal disease. Here, in both murine and human PDA, we demonstrate that extracellular matrix architecture regulates cell extrusion and subsequent invasion from intact ductal structures through tumor-associated collagen signatures (TACS). This results in early dissemination from histologically premalignant lesions and continual invasion from well-differentiated disease, and it suggests TACS as a biomarker to aid in the pathologic assessment of early disease. Furthermore, we show that pancreatitis results in invasion-conducive architectures, thus priming the stroma prior to malignant disease. Analysis in potentially novel microfluidic-derived microtissues and in vivo demonstrates decreased extrusion and invasion following focal adhesion kinase (FAK) inhibition, consistent with decreased metastasis. Thus, data suggest that targeting FAK or strategies to reengineer and normalize tumor microenvironments may have roles not only in very early disease, but also for limiting continued dissemination from unresectable disease. Likewise, it may be beneficial to employ stroma-targeting strategies to resolve precursor diseases such as pancreatitis in order to remove stromal architectures that increase risk for early dissemination.

Authors

Arja Ray, Mackenzie K. Callaway, Nelson J. Rodríguez-Merced, Alexandra L. Crampton, Marjorie Carlson, Kenneth B. Emme, Ethan A. Ensminger, Alexander A. Kinne, Jonathan H. Schrope, Haley R. Rasmussen, Hong Jiang, David G. DeNardo, David K. Wood, Paolo P. Provenzano

×

Figure 5

Inhibition of FAK alters frequency of collagen architectures, extrusion, and metastasis in PDA.

Options: View larger image (or click on image) Download as PowerPoint
Inhibition of FAK alters frequency of collagen architectures, extrusion,...
(A and B) Fluorescence micrographs of stained KPCY sections either treated with (A) vehicle control or (B) FAK inhibitor showing reduction in collagen deposition around ductal structures, smoother ductal boundaries, and reduction in cell extrusion; yellow arrowheads indicate single-cell extrusion events in the control sample. (C and D) Quantification of collagen content in KPC mice shows a reduction in deposition of fibrous collagen in both early (1.5 month) and end-stage mice, with a (D) concomitant reduction in TACS-like architectures in KPC mice. Note, the vast majority of PanIN lesions in FAKi-treated mice still retain TACS-2 and TACS-3 architectures in spite of lower overall collagen levels. (E) Number of extrusion events quantified from control and FAKi-treated mice showing reduced extrusion by FAK inhibition. (F) Extrusion events for the control and FAK inhibited groups quantified as a function of TACS-2 or TACS-3 architectures showing a decrease in extrusion and especially into TACS-3 regions. (G) Frequency of liver metastasis in control and FAKi-treated KPC mice showing reduction in liver metastases with FAK inhibitor treatment (data are from ref. 7). Data are mean — SEM (C–F), n = 29–36 FOV per group for C, n = 3 per group for D–F, and n = 6 for G. ****P < 0.0001, *P < 0.05 by 2-way ANOVA and Sidak’s multiple-comparison test for C, D, and F; *P < 0.05 for E by t test; *P < 0.05 by Fisher’s exact test for G. Scale bars: 50 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts